nitric oxide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Heinz Kähler: Die Augustusstatue von Primaporta. Köln 1959. Erika Simon: Der Augustus von Prima Porta. Bremen, Dorn 1959. (Opus nobile 13) Hans Jucker: Dokumentationen zur Augustusstatue von Primaporta, in: Hefte des Archäologischen Seminars Bern 3 (1977) S. 16–37. Paul Zanker: Augustus und die Macht der Bilder. München, C. H. Beck 1987, ISBN 3-406-32067-8 Kaiser Augustus und die verlorene Republik, Ausstellung Berlin 1988. Mainz, Zabern 1988. S. 386 f. Nr. 215. Erika Simon: Altes und Neues zur Statue des Augustus von Primaporta, in: G. Binder (Hrsg.), Saeculum Augustum, Bd. 3, Darmstadt, WBG 1991, S. 204–233. Dietrich Boschung: Die Bildnisse des Augustus, Gebr. Mann Verlag, Berlin 1993 (Das römische Herrscherbild, Abt. 1, Bd. 2) ISBN 3-7861-1695-4 Thomas Schäfer: Der Augustus von Primaporta im Wechsel der Medien, in: H. J. Wendel u.a. (Hrsg.), Wechsel des Mediums. Zur Interdependenz von Form und Inhalt, Rostock 2001, S. 37–58. Vinzenz Brinkmann und Raimund Wünsche (eds.): Bunte Götter. Die Farbigkeit antiker Skulptur. Eine Ausstellung der Staatlichen Antikensammlungen und Glyptothek München in Zusammenarbeit mit der Ny Carlsberg Glyptotek Kopenhagen und den Vatikanischen Museen, Rom, Staatliche Antikensammlungen und Glyptothek, München 2004 ISBN 3-933200-08-3. In Italian
=== Recommended diet === For the subset of patients whose homocystinuria is caused by cystathionine beta-synthase deficiency (i.e. those that do not respond to B6 supplementation), low-protein food is recommended for this disorder, which requires food products low in particular types of amino acids (e.g., methionine) in addition to supplementation.
Depending on the venue's climate, the turf used was either a hybrid of 84% Kentucky bluegrass and 16% perennial ryegrass (for cooler temperatures), or Bermuda grass (for warmer temperatures). Four venues (Atlanta, Dallas, Houston, and Vancouver) were indoor stadiums that used retractable roof systems, all equipped with climate control, while a fifth, SoFi Stadium in Los Angeles, was open-air but had a translucent roof and no climate control. The host of the final match—MetLife Stadium in East Rutherford, New Jersey—was announced by FIFA on February 4, 2024. Although there were soccer-specific stadiums in Canada and the United States, the largest soccer-specific stadium in the U.S., Geodis Park in Nashville, Tennessee, seated 30,000, fell short of FIFA's minimum requirement of 40,000 seats (Toronto's BMO Field was expanded from 30,000 to 45,500 for this tournament). Stadiums including Mercedes-Benz Stadium in Atlanta; Gillette Stadium in Foxborough, Massachusetts; and Lumen Field in Seattle have been used by both National Football League (NFL) and Major League Soccer (MLS) teams. Although the Canadian and American stadiums were primarily used for gridiron football, they were also designed to accommodate soccer matches. Mexico City was the only capital of the three host nations chosen as a venue site; Ottawa and Washington, D.C., joined Bonn (West Germany, 1974) and Tokyo (Japan, 2002) as the only capital cities not selected to host World Cup matches.
=== 2-D liquid chromatography === By coupling liquid chromatography with a variety of other immunodetection techniques such as serological proteome analysis (SERPA), it is possible to analyze the hydrophobicity, PI, relative mass, and antibody reactivity of antibodies within a given serum.
=== Lawsuits === In April 2012, Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals Inc. were fined $1.2 billion for downplaying multiple risks associated with risperidone. The verdict was later reversed by the Arkansas state supreme court. In August 2012, J&J agreed to pay $181 million to 36 US states to settle claims that it had promoted risperidone and paliperidone for off-label uses including for dementia, anger management, and anxiety. In November 2013, J&J was fined $2.2 billion for illegally marketing risperidone for use in people with dementia and paying kickbacks to prescribing physicians and nursing home pharmacies. In 2015, Steven Brill wrote an investigative journalism piece about J&J in The Huffington Post focused on J&J's marketing of risperidone. J&J has faced numerous civil lawsuits on behalf of children who were prescribed risperidone who grew breasts (a condition called gynecomastia); as of July 2016 there were about 1,500 cases in Pennsylvania state court in Philadelphia, and there had been a February 2015 verdict against J&J with $2.5 million awarded to a man from Alabama, a $1.75 million verdict against J&J that November, and in 2016 a $70 million verdict against J&J. In October 2019, a jury ordered J&J to pay $8 billion in punitive damages to a Pennsylvania man who had grown breasts during adolescence. This verdict amount chosen by the jury was reduced more than 1,000-fold by a judge in January 2020, with the new punitive damages being $6.8 million.
Sources: en.wikipedia.org
18 October – A study indicates there has been a substantial increase of sentiment negativity and decrease of emotional neutrality in headlines across written popular news media since 2000. 19 October – A novel type of effective hydrogen storage using readily available salts is reported. 20 October A study of PNMN, the world's largest no-fishing zone, finds a "spillover benefit" for migratory species like bigeye and yellowfin tuna. The first data transmission to exceed 1 petabit per second (Pbit/s) using only a single laser and a single optical chip is demonstrated by European researchers. 21 October – News outlets report about a novel agricultural robot for viable weed control using lasers or "laserweeding". There are similar precision agriculture machines that have been reported before, also e.g. applying low amounts of herbicides and fertilizers with precision while mapping plant locations, in some cases autonomously. Their benefits may include "healthier crops and soil, decreased herbicide use, and reduced chemical and labor costs". 24 October The NHS launches 'Our Future Health', one of the world's largest health and genetic data gathering projects, aimed at building a long-term repository of information for researchers. Five million UK adults are invited to participate. "Hybrid viral particles (HVPs)" are reported, combining IAV and RSV in vitro. 25 October – A comprehensive annually scheduled study finds climate change is "undermining every dimension of global health monitored" and reports dire conclusions from tracking of impact indicators.
The Bryher Woman was a celtic iron-age woman whose cist grave, containing a mirror and a sword, was discovered on Bryher, Isles of Scilly, in 1999. In 2023, scientists announced that analysis of the tooth fragments showed her to be female.
In May 1972, President Richard M. Nixon and Soviet Premier Leonid Brezhnev negotiated an easing of relations known as détente, creating a temporary "thaw" in the Cold War. The two nations planned a joint mission to dock the last US Apollo craft with a Soyuz, known as the Apollo-Soyuz Test Project (ASTP). To prepare, the US designed a docking module for the Apollo that was compatible with the Soviet docking system, which allowed any of their craft to dock with any other (e.g. Soyuz-to-Soyuz as well as Soyuz-to-Salyut). The module was also necessary as an airlock to allow the men to visit each other's craft, which had incompatible cabin atmospheres. The USSR used the Soyuz 16 mission in December 1974 to test modifications of the Soyuz atmosphere and the docking adapter to prepare for ASTP. The joint mission began when Soyuz 19 was first launched on July 15, 1975, at 12:20 UTC, and the Apollo craft was launched with the docking module six and a half hours later. The two craft rendezvoused and docked on July 17 at 16:19 UTC. The three astronauts conducted joint experiments with the two cosmonauts, and the crew shook hands, exchanged gifts, and visited each other's craft.
Islam is the state religion, with freedom of religion guaranteed by the constitution. The majority are Muslims (96.35%), followed by Hindus (2.17%) and Christians (1.37%). Other minorities include Sikhs, Buddhists, Jains, Zoroastrians (Parsi), and the unique Kalash people who practice animism. In 2012, 2% of the population identified as atheist in a Gallup survey.
A norepinephrine and dopamine disinhibitor (NDDI or NDD) is a drug that acts at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain. Agomelatine, an antidepressant which disinhibits norepinephrine and dopamine release in the frontal cortex by antagonizing 5-HT2C receptors, was the first drug to be described as an NDDI. While many other drugs also antagonize 5-HT2C receptors to some degree or another, they tend to be very non-specific in their actions, and as a result, the term "NDDI" has generally, though not always (for instance, fluoxetine has been called an NDDI in addition to SSRI due to its (weak) blockade of 5-HT2C), been reserved for describing newer, more selective agents in which disinhibition of norepinephrine and dopamine release is their primary mechanism of action. Another drug that has been referred to as an NDDI in the medical literature is flibanserin, which is approved as a treatment for hypoactive sexual desire disorder in premenopausal women. Flibanserin disinhibits norepinephrine and dopamine release in the prefrontal cortex by activating postsynaptic 5-HT1A receptors in this area. Aside from agomelatine, fluoxetine, flibanserin, mianserin and mirtazapine, as of present, no other drugs have been described as NDDIs in the medical literature, despite the fact that many other existing drugs possess effects consistent with those of the definition of an NDDI. In any case, more drugs labeled specifically as NDDIs may be seen in the future.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.